BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, December 13, 2024
Breaking News: Healing a health divide (that’s long overdue)
See today's BioWorld Science
Home
» V1A agonist PHIN-214 shows promise for cirrhosis-associated portal hypertension
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Gastrointestinal
V1A agonist PHIN-214 shows promise for cirrhosis-associated portal hypertension
Jan. 16, 2024
No Comments
There are several factors that induce cirrhosis. During cirrhosis, there is an increased intrahepatic resistance to blood flow, leading to portal hypertension, among others, where portal vein pressure is increased.
BioWorld Science
Gastrointestinal